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Atrial Fibrillation and
Sinus Node Dysfunction
We have read with great interest the article by Lombardi et al. (1),
which used analysis of heart rate variability (HRV) to predict
recurrence of atrial fibrillation (AF) after electrical cardioversion.
Although analysis of HRV in this setting is technically demanding
(owing to ectopy) the investigators showed that patients with an
early recurrence of AF (within two weeks after cardioversion) are
characterized by a high low-frequency/high-frequency ratio com-
pared to patients who maintain sinus rhythm. Based on the
implicit assumption that HRV reflects autonomic modulation of
the sinus node, Lombardi et al. (1) concluded that sympathetic
modulation is increased in these patients. However, it is question-
able whether this assumption is valid in the present setting. For the
sinus node to reflect autonomic modulation it is required that sinus
node function as such is normal. In other words, in case of intrinsic
dysfunction, the sinus node is not an adequate “thermometer,” and
HRV should not be used to assess autonomic modulation. In
patients with persistent AF there is reason to doubt whether
intrinsic sinus node function is normal.
First, AF is often associated with sick sinus syndrome (2). In
fact, histopathological studies demonstrated that persistent AF is
associated with significant damage to the sinus node, the perinodal
tissue and the sinus node artery (3). Second, and possibly even
more important, AF per se causes sinus node dysfunction.
In an experimental pacing-model in dogs, Elvan et al. (4)
examined the effect of AF on sinus node function. Intrinsic
function was assessed after pharmacological autonomic blockade
using propranolol and atropine. No effect was apparent after 1 h of
AF, but prolonged AF (two to six weeks) caused a significant
increase in intrinsic-corrected sinus node recovery time and a
decrease in intrinsic heart rate. Within one week after cessation of
AF these measures of sinus node function gradually returned to
normal. Comparable data have recently been reported in humans
(5). It thus appears that electrical remodeling secondary to AF is
not confined to the atrial myocardium but also involves the sinus
node.
The clinical data provided by Lombardi et al. (1) on their
patients do not indicate intrinsic sinus node dysfunction. Con-
versely, intrinsic sinus node dysfunction is hard to rule out.
Therefore, we believe that the conclusion by Lombardi et al. (1),
namely that patients with early recurrence of AF show signs of
increased sympathetic modulation, should be toned down.
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REPLY
The letter of van den Berg and van Gelder questions whether
electrical remodeling of the sinus node might affect interpretation
of heart rate variability parameters measured after successful
cardioversion of chronic atrial fibrillation (AF).
The issue is of relevance and must be considered within a recent
number of observations indicating the complexity of the electrical
remodeling process in relation not only to AF duration but also to
different atrial sites and sinus node involvement.
We have recently reported (1) that after successful electrical
cardioversion of chronic AF in patients pre-treated with amioda-
rone, the presence of a distinct short-term heart rate variability
pattern characterized by an low frequency/high frequency (LF/
HF) ratio 2 is associated with an 8-fold increased risk of early
recurrence. In contrast, patients with a LF/HF ratio2 were more
likely to maintain sinus rhythm.
We therefore concluded that signs of increased sympathetic and
reduced vagal modulation of the sinus node were characteristic of
patients with an early AF recurrence, and we hypothesized that
abnormal autonomic control could play a pro-arrhythmic role by
influencing electrical remodeling.
We are aware of the data suggesting that, in patients with
chronic atrial flutter, signs of electrical remodeling of sinus node
can be detected after cardioversion (2). However, in our opinion, it
is difficult to evaluate the clinical significance of these findings
obtained during pharmacological autonomic blockade and their
possible effect on spectral parameters of heart rate variability. Two
factors seem to deny this possibility. First, we observed an increase
rather than a decrease in low frequency oscillations in patients with
early recurrence of atrial fibrillation. This pattern, together with
reduction of the high-frequency oscillation, is unlikely to reflect a
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sinus node dysfunction. Second, total power (i.e., a quantitative
measure of heart rate variability) was similar both in patients with
early recurrence and in subjects who maintained sinus rhythm.
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Over-AVID Subgroup Analysis
Given the extensive time, effort and expense involved in perform-
ing large-scale clinical trials, there is a natural tendency to perform
subgroup analyses on the accumulated data subsequent to termi-
nation of the trial. Assmann et al. (1) recently stated: “Subgroup
analyses are particularly prone to overinterpretation, and one is
tempted to suggest “don’t do it” (or at least “don’t believe it”) for
many trials, but this suggestion is probably contrary to human
nature.” The report by Hallstrom et al. (2), a subgroup analysis of
the Antiarrhythmics Versus Implantable Defibrillators (AVID)
trial (3), falls into the category of “don’t believe it.”
The hypothesis of this substudy is reasonable—there may be
subgroups of AVID patients who do not benefit from an implant-
able defibrillator as opposed to amiodarone therapy. Based on their
data, the authors (2) conclude that the lowest-risk sextile is a
subgroup in which implantable defibrillators may not offer benefit.
However, this conclusion is faulty as the design of this substudy
forces the outcome to be negative.
The AVID trial (3) evaluated whether the strategy of antiar-
rhythmic drug therapy versus implantable defibrillator therapy is
better for treating patients with hemodynamically significant
ventricular tachycardia or ventricular fibrillation. In designing the
study, the investigators (4) concluded that a sample size of 1,200
patients was required to demonstrate the predicted benefit. The
trial was terminated early, after only 1,096 patients were enrolled,
because the analysis revealed that the difference in the primary
outcome variable had crossed the statistical boundary for early
termination. In the current report (3), the analysis of relative
benefit between antiarrhythmic drugs and the implantable defi-
brillator relies on a sample size that is one-sixth the total sample
size of the AVID trial. In addition to the small sample size, the
subgroup being investigated is the group of patients in which the
event rate and mortality is lowest. In subgroups with lower event
rates, the difference between event rates in the two treatment
groups typically decreases and a larger sample size is required to
demonstrate that the difference is significant. It is misleading to
suggest that one could demonstrate a difference in survival in the
lowest-risk sextile with the sample size that is available.
Study sample size is typically chosen so that the power of the
study or the probability of detecting the postulated difference is
high, typically in the 80% to 90% range. The calculated power of
this AVID substudy is 5.5% (calculated using a sample size of 166
patients, two year mortality of 11% [which was the observed
mortality], a 25% reduction in mortality to 8.25% by one of the
treatments), a value substantially less than the 80% to 90% value
used in designing a trial. This means that there was only a minimal
chance that this report could have demonstrated a difference
between the two therapies even if implantable defibrillators or
amiodarone reduced mortality by as much as 25%.
These substudy results should be interpreted as inadequate to
answer the question posed by the investigators. The data are
consistent with no benefit of implantable defibrillator over amio-
darone therapy, with a benefit of implantable defibrillator therapy
over amiodarone therapy and with a benefit of amiodarone therapy
over implantable defibrillator therapy. In contrast, the clinical
characteristics that identify the low risk sextile are interesting. A
suggestion that the cost-effectiveness in this low risk sextile may be
less favorable than in the other sextiles may also be valid. However,
only properly designed clinical trials will be able to address the
question of which therapy is appropriate or better in patients who
have a low arrhythmia risk. Until such studies are performed, one
can only conclude based upon the AVID trial that the strategy of
implantable defibrillator therapy has a survival benefit compared to
the strategy of antiarrhythmic drug therapy (amiodarone) in
patients who have suffered either ventricular fibrillation or hemo-
dynamically significant ventricular tachycardia.
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REPLY
We agree with Goldberger et al. that subgroup analyses are prone
to overinterpretation. One must be very cautious in dealing with
subgroup analyses, particularly when they are post hoc (ours was a
priori), based on essentially randomly defined subgroups (ours was
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